Solving CNS Clinical Trials
Many neurologic disorders, such as ADHD, Alzheimer’s, depression, epilepsy, Parkinson’s disease, sclerosis, or schizophrenia, lack objective, easily measurable outcomes.
As complex neurological disease mechanisms are difficult to collect and interpret across heterogeneous patient populations, CNS clinical trials are often expensive and difficult to fund, especially for rare conditions.
Diagnosed based on a combination of cognitive, behavioral, and functional symptoms, clinical trials in neurology, particularly for central nervous system (CNS) disorders, present unique data capture and analysis challenges for patients, sites, study teams, and other stakeholders.
Measuring CNS Clinical Trials Outcomes
It also integrates cognitive, mobility, and voice assessments using mobile, wearables, and sensor technology to work with a variety of CNS questionnaires and assessments, including:
- Hoehn and Yahr
Leading the Way for CNS Biomarkers
Neurology often lacks biomarkers that are sensitive, specific, and noninvasive which can be a challenge for trials. Leading the way in digital biomarkers technology, Clinical ink offers the best-in-class analytics platform to capture, collect, and interpret real-time data powering the evaluation and development of new CNS treatments.
Our technology and tools are configurable for CNS study sites, so all stakeholders can easily and efficiently manage clinical trial data and gain:
- Focused and valuable site interactions
- Complex constructions and scoring, and multimedia sources for CNS studies
- Large enrollment volumes and quick enrollment capabilities
- Optimized review of specialized document, audio, image, and video capture